Atlas Trials

Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma

Clinical trial NCT01616199 · TERMINATED

Trial details

NCT number
NCT01616199
Sponsor
Cascadian Therapeutics Inc.
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Advanced BRAF-mutant Cancers
Start date
2012-08-01
Primary completion
2014-12-01
Enrollment
24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.